IP Library › Granted Patent US 9,993,442
Granted Patent B2
US 9,993,442 · App. 14/832,649 · Granted Jun 12, 2018

Method for the treatment or prevention of lower urinary tract symptoms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,993,442
App. No.
14/832,649
Granted
Jun 12, 2018
Kind
B2
Abstract

This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

Claims (10)

1. A method for treatment of lower urinary tract symptoms with or without pelvic pain in a male individual, said method comprising administering to the individual an effective amount of (Z)-2-{2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethoxy}ethanol (fispemifene), or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof, wherein the lower urinary tract symptoms comprise micturition frequency, micturition urgency, nocturia, or interstitial cystitis.

2. The method according to claim 1 wherein the lower urinary tract symptoms comprise interstitial cystitis.

3. The method according to claim 1 wherein the lower urinary tract symptoms comprise micturition frequency.

4. The method according to claim 1 wherein the lower urinary tract symptoms comprise micturition urgency.

5. The method according to claim 1 wherein the lower urinary tract symptoms comprise nocturia.

6. The method according to claim 1 wherein the method comprises administering to the individual an effective amount of fispemifene.

7. The method according to claim 2 wherein the method comprises administering to the individual an effective amount of fispemifene.

8. The method according to claim 3 wherein the method comprises administering to the individual an effective amount of fispemifene.

9. The method according to claim 4 wherein the method comprises administering to the individual an effective amount of fispemifene.

10. The method according to claim 5 wherein the method comprises administering to the individual an effective amount of fispemifene.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2017
From: SANTTI, RISTO; STRENG, TOMI
To: HORMOS MEDICAL CORPORATION
Reel/Frame 043074/0161 →